The oncogenic transcription factor C/EBPβ is an emerging therapeutic target for many cancers. Rotolo and colleagues present data describing ST101, a peptide antagonist that prevents C/EBPβ dimerization and enhances its proteasome-dependent degradation. ST101 attenuates C/EBPβ target gene expression, resulting in tumor-specific cytotoxicity in glioblastoma, breast, melanoma, prostate, and lung cancer cells, while normal human epithelial cells are not impacted. In vivo xenograft models indicate that ST101 induces potent tumor growth inhibition or regression, both as a single agent and in combination studies. These data identify ST101 as a promising therapeutic against C/EBPβ-dependent cancers.

Sarcomas are malignant mesenchymal tumors for which radical resection is standard of care for localized disease. However, complete resection is often not achieved and locoregional recurrence rates are as high as 84%. Although classically chemoresistant, including paclitaxel (PTX), Blessing and colleagues demonstrate prolonged cell-cycle arrest, mitotic catastrophe, subsequent apoptosis, and irreversible cell death in CS-1 as well...

You do not currently have access to this content.